New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
07:33 EDTEPZMEpizyme reports Q2 EPS (40c), consensus (50c)
Reports Q2 revenue $9.49M, consensus $7.58M. Expects to end 2014 with more than $170M in cash and cash equivalents, it believes will fund the company until at least mid-2016, prior to including any potential future milestone payments.
News For EPZM From The Last 14 Days
Check below for free stories on EPZM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:05 EDTEPZMEpizyme names Peter Ho as Chief Development Officer
Epizyme announced the appointments of Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D. as Vice President, Business Development. Ho will lead Epizyme’s clinical development, regulatory and translational medicine functions. Shih will lead Epizyme’s partnership strategy and execution.
September 12, 2014
10:00 EDTEPZMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:27 EDTEPZMEpizyme initiated with a Buy at Mizuho
Target $35.
September 4, 2014
11:01 EDTEPZMEpizyme management to meet with Maxim
Cocktails and Group dinner to be held in New York on September 8 at 5:30 pm hosted by Maxim.
September 2, 2014
16:59 EDTEPZMEpizyme announces resignation of CFO
Subscribe for More Information
16:31 EDTEPZMEpizyme announces resignation of CFO Jason Rhodes and succession plan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use